CEO Phillip Chan highlighted a 25% growth in Q4 product revenue, reaching $9.2 million, and $35.6 million in total product revenue for 2024, representing a 15% annual growth. He emphasized strong ...
A clinical-stage oncology company developing targeted therapies that exploit DNA damage response (DDR) vulnerabilities in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results